{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:38:32Z","timestamp":1649165912932},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11739-018-1834-x","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T16:06:46Z","timestamp":1521648406000},"page":"1019-1028","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome"],"prefix":"10.1007","volume":"13","author":[{"given":"Ilaria","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","volume":"46","author":"V Fuster","year":"2005","unstructured":"Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ (2005) Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46:937\u2013954","journal-title":"J Am Coll Cardiol"},{"key":"1834_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1160\/TH12-10-0772","volume":"109","author":"R Caterina De","year":"2013","unstructured":"De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI (2013) European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 109:569\u2013579","journal-title":"Thromb Haemost"},{"key":"1834_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1160\/TH16-12-0963","volume":"117","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Angiolillo DJ, Huber K (2017) Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 117:1240\u20131248","journal-title":"Thromb Haemost"},{"key":"1834_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsk\u00fd P, ESC Scientific Document Group (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 39:119\u2013177","journal-title":"Eur Heart J"},{"key":"1834_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","volume":"378","author":"G Montalescot","year":"2011","unstructured":"Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C, B\u00e9nezet J-F, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet J-P, Vicaut E, ATOLL Investigators (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378:693\u2013703","journal-title":"Lancet"},{"key":"1834_CR6","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1136\/bmj.e553","volume":"344","author":"J Silvain","year":"2012","unstructured":"Silvain J, Beygui F, Barth\u00e9l\u00e9my O, Pollack C, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet J-P, Vicaut E, Montalescot G (2012) Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 344:e553","journal-title":"BMJ"},{"key":"1834_CR7","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218\u20132230","journal-title":"N Engl J Med"},{"key":"1834_CR8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","volume":"369","author":"PG Steg","year":"2013","unstructured":"Steg PG, Van\u2019t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell\u2019 Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P (2013) Bivalirudin started during emergency transport for primary PCI. N Engl J Med 369:2207\u20132217","journal-title":"N Engl J Med"},{"key":"1834_CR9","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","volume":"35","author":"S Schulz","year":"2014","unstructured":"Schulz S, Richardt G, Laugwitz K-L, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tolg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A, Kastrati A, Mehilli J, Richardt G, Mehran R, Gershlick A, Mehilli J, Burgdorf C, Byrne RA, Cassese S, Fusaro M, Hausleiter J, Hengstenberg C, Joner M, Kasel M, Kastrati A, Massberg S, Ott I, Pache J, Schunkert H, Seyfarth M, Sibbing D, Tiroch K, Laugwitz K-L, Ibrahim T, Hoppmann P, Schneider S, Bradaric C, Richardt G, Abdel-Wahab M, Geist V, Schwarz B, Sulimov D, Tolg R et al (2014) Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 35:2285\u20132294","journal-title":"Eur Heart J"},{"key":"1834_CR10","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH (2014) Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384:1849\u20131858","journal-title":"Lancet"},{"key":"1834_CR11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW (2015) Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction. JAMA 313:1336\u20131346","journal-title":"JAMA"},{"key":"1834_CR12","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/eurheartj\/ehu214","volume":"35","author":"U Zeymer","year":"2014","unstructured":"Zeymer U, Van\u2019t Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG (2014) Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J 35:2460\u20132467","journal-title":"Eur Heart J"},{"key":"1834_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/2048872615572599","volume":"5","author":"D Capodanno","year":"2016","unstructured":"Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW (2016) Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care 5:253\u2013262","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Frigoli E, Leonardi S, Rothenb\u00fchler M, Gagnor A, Calabr\u00f2 P, Garducci S, Rubartelli P, Briguori C, And\u00f2 G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, Van\u2019t Hof A, Boccuzzi G, Omerovic E, Sabat\u00e9 M, Heg D, J\u00fcni P, Vranckx P, MATRIX Investigators (2015) Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 373:997\u20131009","journal-title":"N Engl J Med"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, Fr\u00f6bert O, Linder R, Danielewicz M, Hamid M, Swahn E, Henareh L, Wagner H, H\u00e5rdhammar P, Sj\u00f6gren I, Stewart J, Grimfj\u00e4rd P, Jensen J, Aasa M, Robertsson L, Lindroos P, Haupt J, Wikstr\u00f6m H, Ulvenstam A, Bhiladvala P, Lindvall B, Lundin A, T\u00f6dt T, Ioanes D, R\u00e5munddal T, Kellerth T, Zagozdzon L, G\u00f6tberg M, Andersson J, Anger\u00e5s O, \u00d6stlund O, Lagerqvist B, Held C, Wallentin L, Scherst\u00e9n F, Eriksson P, Koul S, James S (2017) Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 377:1132\u20131142","journal-title":"N Engl J Med"},{"key":"1834_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol \u00c7, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GYH, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J, Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37:267\u2013315","journal-title":"Eur Heart J"},{"key":"1834_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","volume":"28","author":"SA Murphy","year":"2007","unstructured":"Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E (2007) Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28:2077\u20132086","journal-title":"Eur Heart J"},{"key":"1834_CR18","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJMoa055443","volume":"354","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG, Bassand J-P, Wallentin L, Joyner C, Fox KAA (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464\u20131476","journal-title":"N Engl J Med"},{"key":"1834_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jacc.2009.03.062","volume":"54","author":"SS Jolly","year":"2009","unstructured":"Jolly SS, Faxon DP, Fox KAA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR (2009) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 54:468\u2013476","journal-title":"J Am Coll Cardiol"},{"key":"1834_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.2010.1320","volume":"304","author":"PG Steg","year":"2010","unstructured":"Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht H-J, L\u00f3pez-Send\u00f3n JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S (2010) Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial. JAMA 304:1339\u20131349","journal-title":"JAMA"},{"key":"1834_CR21","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"GW Stone","year":"2006","unstructured":"Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203\u20132216","journal-title":"N Engl J Med"},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"1834_CR23","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"1834_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"1834_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527\u2013533","journal-title":"Lancet"},{"key":"1834_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS (2005) Addition of clopidogrel to aspirin in 45\u2008852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607\u20131621","journal-title":"Lancet"},{"key":"1834_CR27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, L\u00f3pez-Send\u00f3n JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179\u20131189","journal-title":"N Engl J Med"},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"1834_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng C-D, Merkely B, Gasparovic V, Corbalan R, Cintez\u0103 M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367:1297\u20131309","journal-title":"N Engl J Med"},{"key":"1834_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thors\u00e9n M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"1834_CR31","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/eurheartj\/ehu160","volume":"35","author":"D Lindholm","year":"2014","unstructured":"Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK (2014) Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 35:2083\u20132093","journal-title":"Eur Heart J"},{"key":"1834_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LHK, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20\u201333","journal-title":"N Engl J Med"},{"key":"1834_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/2048872614527838","volume":"3","author":"C Held","year":"2014","unstructured":"Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, Moliterno DJ, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW (2014) Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care 3:246\u2013256","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404\u20131413","journal-title":"N Engl J Med"},{"key":"1834_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA (2012) Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 380:1317\u20131324","journal-title":"Lancet"},{"key":"1834_CR36","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.114.015042","volume":"132","author":"EA Bohula","year":"2015","unstructured":"Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA (2015) The efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with prior myocardial infarction and no history of stroke or TIA: results from TRA 2 P-TIMI 50. Circulation 132:1871\u20131879","journal-title":"Circulation"},{"key":"1834_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143:241\u2013250","journal-title":"Ann Intern Med"},{"key":"1834_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai GGL, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27:519\u2013526","journal-title":"Eur Heart J"},{"key":"1834_CR39","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","volume":"28","author":"PP Karjalainen","year":"2007","unstructured":"Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M-A, Airaksinen TJ, Niemel\u00e4 M, Vahlberg T, Airaksinen KEJ (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28:726\u2013732","journal-title":"Eur Heart J"},{"key":"1834_CR40","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, S\u00f8rensen R, Clausen MT, Fog-Petersen ML, Rauns\u00f8 J, Gadsb\u00f8ll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstr\u00f8m SZ, Poulsen HE, K\u00f8ber L, Torp-Pedersen C (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433\u20131441","journal-title":"Arch Intern Med"},{"key":"1834_CR41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969\u2013974","journal-title":"N Engl J Med"},{"key":"1834_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","volume":"360","author":"RF Es van","year":"2002","unstructured":"van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360:109\u2013113","journal-title":"Lancet"},{"key":"1834_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"key":"1834_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699\u2013708","journal-title":"N Engl J Med"},{"key":"1834_CR45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","volume":"66","author":"CN Hess","year":"2015","unstructured":"Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FWA, De Caterina R, Ogawa H, Wallentin L, Alexander JH (2015) Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 Trial. J Am Coll Cardiol 66:777\u2013787","journal-title":"J Am Coll Cardiol"},{"key":"1834_CR46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJM Dewilde","year":"2013","unstructured":"Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, Adriaenssens T, Vrolix M, Heestermans AACM, Vis MM, Tijsen JGP, Van\u2019t Hof AW, ten Berg JM, WOEST study investigators (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107\u20131115","journal-title":"Lancet"},{"key":"1834_CR47","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"KA Fiedler","year":"2015","unstructured":"Fiedler KA, Maeng M, Mehilli J, Schulz-Sch\u00fcpke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz K-L, Kastrati A, Sarafoff N (2015) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 65:1619\u20131629","journal-title":"J Am Coll Cardiol"},{"key":"1834_CR48","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"1834_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"},{"issue":"17","key":"1834_CR50","doi-asserted-by":"publisher","first-page":"31932","DOI":"10.1016\/j.amjcard.2017.12.014","volume":"9149","author":"I Cavallari","year":"2017","unstructured":"Cavallari I, Patti G (2017) Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 9149(17):31932. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2017.12.014\n                    \n                   (epub ahead of print)","journal-title":"Am J Cardiol"},{"key":"1834_CR51","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(17)30760-2","volume":"389","author":"PA Gurbel","year":"2017","unstructured":"Gurbel PA, Tantry US (2017) GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet 389:1773\u20131775","journal-title":"Lancet"},{"key":"1834_CR52","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, G\u00fcray \u00dc, Park D-W, Bode C, Welsh RC, Gibson CM (2017) Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389:1799\u20131808","journal-title":"Lancet"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-018-1834-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:26:04Z","timestamp":1553127964000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-018-1834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s11739-018-1834-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"7 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}